BostonGene, a provider of AI-driven molecular and immune profiling solutions, has been named as a qualified contract research organization (CRO) of Akoya Biosciences.
 
By combining Akoya’s single-cell imaging solutions with BostonGene’s expertise in spatial proteomics sample processing and analysis, researchers will gain access to the intricate landscape of cellular biology, paving the way for discoveries and effective therapeutic strategies.
 
Akoya offers a suite of high-throughput automated multiplex immunofluorescence platforms, reagents, and ready-to-use PhenoCode panels. Akoya’s PhenoCycler-Fusion and PhenoImager HT platforms are at the forefront of spatial biology and offer significant advancements in speed and scale for high-parameter tissue analysis.
 
As a qualified CRO of Akoya, BostonGene will perform multiplex immunofluorescence and analysis using Akoya’s high-plex PhenoCycler-Fusion and PhenoImager HT whole slide imaging platforms, harmonizing wet lab processing with advanced bioinformatics providing end-to-end imaging solutions for life sciences researchers, advancing the understanding of complex biological processes and supporting the development of personalized therapies.
 
“With our PhenoCycler-Fusion and PhenoImager HT platforms, BostonGene can offer spatial phenotyping services to enable the acceleration of immunotherapy discovery and development in biopharma and academic settings,” said David Petrillo, VP – Americas Sales at Akoya. “We are delighted BostonGene is now part of our global network of qualified CRO service providers.”
 
“We look forward to leveraging Akoya’s solutions for streamlined high-throughput multiplex immunofluorescence experiments,” said Zhongming Xiang, PhD, Principal Scientist, Imaging at BostonGene “Akoya’s state-of-the-art technologies will enable comprehensive and precise research, ultimately advancing our mission to revolutionize precision medicine and improve patient outcomes.”